Skip to main content
    C

    Cellebrite DI (CLBT)

    Official site

    TECHNOLOGY • SOFTWARE - INFRASTRUCTURE • NASDAQ

    $11.12
    -0.41 (-3.56%)

    Market Cap: $2.90B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cellebrite DI (CLBT) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cellebrite DI (CLBT) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Cellebrite DI reported EPS of $0.13, above the $0.12 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    73%(16/22)
    Avg Surprise
    +58.86%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 9, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.18
    Range$0.16 - $0.20
    10 analysts
    Revenue Consensus
    $149.93M
    Range$142.10M - $157.50M
    10 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.14
    Range$0.12 - $0.17
    6 analysts
    EPS Revisions
    2
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.14+4.1%
    60d ago$0.14+4.1%
    30d ago$0.14+4.1%
    7d ago$0.14+4.1%
    Current$0.14
    Revenue Consensus
    $145.61M
    Range$142.00M - $152.65M
    6 analysts

    Next Report

    CLBT has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 28.6% above the $0.14 reported for the quarter ended Dec 31, 2025.

    CLBT Earnings Call

    The latest CLBT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, CLBT beat 16, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $149.02M, up 18.2% from $126.03M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.13$0.12N/A+8.33%Beat-7.1%85 up, 3 downNov 12, 2026$149.02M
    Jun 30, 2026$0.05$0.09$0.09 - $0.13-44.44%Miss-58.3%82 up, 3 downAug 13, 2026$131.14M
    Mar 31, 2026$0.12$0.10$0.08 - $0.11+20.00%Beat+20.0%60 up, 3 downMay 14, 2026$128.30M
    Dec 31, 2025$0.14$0.14$0.11 - $0.160.00%In line+40.0%84 up, 3 downFeb 11, 2026$128.82M
    Sep 30, 2025$0.14$0.13$0.11 - $0.14+7.69%Beat0.0%83 up, 3 downNov 12, 2025$126.03M
    Jun 30, 2025$0.12$0.11$0.11 - $0.14+9.09%Beat+20.0%80 up, 1 downAug 14, 2025$113.28M
    Mar 31, 2025$0.10$0.09$0.07 - $0.10+11.11%Beat+25.0%83 up, 0 downMay 14, 2025$107.55M
    Dec 31, 2024$0.10$0.10$0.08 - $0.110.00%In line-16.7%82 up, 5 downFeb 13, 2025$109.05M
    Sep 30, 2024$0.14$0.09-$0.05 - $0.12+55.56%Beat+55.6%70 up, 0 downNov 6, 2024$106.86M
    Jun 30, 2024$0.10$0.05-$0.07 - $0.08+100.00%Beat+100.0%80 up, 1 downAug 15, 2024$95.71M
    Mar 31, 2024$0.08$0.06$0.05 - $0.06+33.33%Beat+166.7%60 up, 0 downMay 23, 2024$89.58M
    Dec 31, 2023$0.12$0.06$0.05 - $0.07+100.00%Beat+50.0%50 up, 0 downFeb 15, 2024$93.01M
    Sep 30, 2023$0.09$0.05$0.04 - $0.05+80.00%Beat+800.0%40 up, 0 downNov 14, 2023$84.18M
    Jun 30, 2023$0.05$0.02$0.01 - $0.03+150.00%Beat-70.6%61 up, 0 downAug 8, 2023$76.68M
    Mar 31, 2023$0.03$0.02$0.01 - $0.04+50.00%Beat+200.0%40 up, 0 downMay 10, 2023$71.23M
    Dec 31, 2022$0.08$0.07N/A+14.29%Beat+166.7%40 up, 0 downFeb 15, 2023$74.02M
    Sep 30, 2022$0.01$0.02$0.00 - $0.04-50.00%Miss-87.5%40 up, 0 downNov 17, 2022$71.67M
    Jun 30, 2022$0.17$0.03$0.00 - $0.05+466.67%Beat+240.0%50 up, 0 downAug 11, 2022$62.57M
    Mar 31, 2022$0.01$0.02-$0.01 - $0.04-50.00%Miss-95.5%40 up, 0 downMay 12, 2022$62.38M
    Dec 31, 2021$0.03$0.02$0.01 - $0.03+50.00%BeatN/A40 up, 0 downFeb 16, 2022$67.91M
    Sep 30, 2021$0.08$0.02$0.02 - $0.02+300.00%BeatN/A2N/ANov 10, 2021$65.89M
    Jun 30, 2021$0.05$0.06N/A-16.67%MissN/A1N/AAug 6, 2021$59.17M
    Mar 31, 2021$0.22N/AN/AN/AN/AN/AN/AN/AMay 17, 2021$53.28M
    Dec 31, 2020-$0.20N/AN/AN/AN/AN/AN/AN/AMar 24, 2021$57.17M
    Sep 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 16, 2020$53.24M
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.50, up 19.0% from the year before. It was -$0.20 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.50+19.0%
    Dec 31, 2024$0.42+44.8%
    Dec 31, 2023$0.29N/A
    Dec 31, 2022$0.27-28.9%
    Dec 31, 2021$0.38N/A
    Dec 31, 2020-$0.20N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,66213
    2026Q2Jun 30, 20266,36414
    2026Q1Mar 31, 20268,34313
    2025Q4Dec 31, 20255,57211
    2025Q3Sep 30, 20258,66114
    2025Q2Jun 30, 20258,78214
    2025Q1Mar 31, 20258,19511
    2024Q4Dec 31, 20248,15014

    2026Q3 Earnings Call

    Opening remarks

    Andrew Kramer Vice President of Investor Relations Thank you, operator, and welcome to Cellebrite's Third Quarter 2026 Financial Results Call. I'm joined here this morning by our primary speakers: Shiven Ramji, Cellebrite's CEO, and David Barter, Cellebrite's CFO. Marcus Jewell, our CRO, will join for a Q&A session. This call is being recorded, and a replay will be made available on our website shortly after the call, along with a copy of our prepared remarks. Please note that today's press release and financial statements, including GAAP-to-non-GAAP reconciliations, are available on the Investor Relations website at investors.cellebrite.com. In addition to the press release, we posted other materials on the quarterly results page of our IR website, including a presentation to accompany our remarks, and that is embedded in your webcast viewer. We also added a link to a customer video, as well as our historical financial information and supplemental data for the first three quarters of 2026, each quarter of 2025, and the full years 2024 and 2023. Additionally, unless stated otherwise, our discussion of our third-quarter 2026 financial metrics, as well as the financial metrics provided in our outlook, will be done on a non-GAAP basis only, and all historical comparisons are with the comparable periods of 2025. I'd like to remind you that today's discussion will contain forward-looking statements, including, but not limited to, the company's business, operations, and financial performance. All forward-looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward-looking statements not to occur. Actual results could also differ materially from historical results and/or from forecasts. Some of these forward-looking statements are discussed under the heading Risk Factors and elsewhere in the company's annual report on Form 20-F filed with the SEC on March 3, 2026. The company does not undertake to update any forward-looking statements to reflect future events or circumstances. Slide 3 outlines the agenda for today. And with that said, I'd now like to turn the call over to Shiven Ramji.

    Shiven Ramji CEO Thank you, Andy, and good morning, everyone. Cellebrite executed better in Q3, with ARR, revenue, and adjusted EBITDA all finishing above our guidance. Our ARR and revenue growth were driven by strong international performance, while our U.S. federal business continued reaccelerating. Our top-line performance, combined with prudent spending, led to strong adjusted EBITDA and free cash flow. Together with our ARR growth, that produced another strong quarter of Rule of X performance. Dave will walk you through the quarterly performance details and our updated outlook. During the quarter, we made important strategic and operational progress. From a strategic perspective, I'm particularly excited about the direction of our product team and what we'll be releasing to customers.

    Frequently Asked Questions About CLBT

    When is Cellebrite DI's next earnings date?

    Cellebrite DI's next earnings report is expected for Feb 9, 2027.

    Did CLBT beat earnings estimates last quarter?

    Yes. Cellebrite DI reported EPS of $0.13 for the quarter ended Sep 30, 2026, above the $0.12 estimate, a 8.33% surprise.

    What EPS do analysts expect from CLBT next quarter?

    The consensus EPS estimate for Cellebrite DI for the quarter ending Dec 31, 2026 is $0.18 from 10 analysts, with estimates from $0.16 to $0.20.

    How often does CLBT beat earnings estimates?

    Cellebrite DI beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.47%.